- Company
- 1 in 3 don't know the right dose of antipyretic drugs
- by Apr 20, 2022 06:05am
- With COVID-19, 9 out of 10 consumers have purchased antipyretic drugs within the past six months, but one in three still does not know the appropriate dosage, indicating that appropriate medication guidance is needed. Johnson & Johnson Korea announced the results of a survey conducted on 1,000 consumers aged 20 to 49 in Korea on the 18th through
- Company
- Hanmi leads the outpatient prescription market in Q1 2022
- by Chon, Seung-Hyun Apr 19, 2022 05:53am
- Hanmi Pharmaceutical’s performance stood out in the outpatient prescription market with its solidified lead heralded by the introduction of its new combination drug. Daewon Pharmaceutical’s prescription volume has also soared vertically due to the boom in anti-inflammatory and cold medicines following a surge in the number of confirmed COVID-1
- Company
- The prolonged slump in IPO of pharmaceutical bio
- by Kim, Jin-Gu Apr 19, 2022 05:52am
- Amid the prolonged sluggish trend in the IPO market in the pharmaceutical bio industry, attention is being paid to whether newly challenged companies will be able to draw a turnaround. According to the pharmaceutical industry on the 19th, there are two pharmaceutical bio companies that have been listed in the second quarter of this year, Wont
- Product
- Immunity products fare better “targeting the long COVID mkt
- by Apr 19, 2022 05:52am
- The OTC drug trend at pharmacies is changing. Compared to February and March when the Omicron variant had wielded power over the country and sales at pharmacies increased due to a surge in demand for antipyretic analgesics and sore throat treatments, etc., sales of products related to long-term effects of COVID-19 are now increasing due to more
- Policy
- MFDS requested supplementary data of Mifepristone
- by Lee, Hye-Kyung Apr 19, 2022 05:52am
- 'The MFDS is conducting a comprehensive review including the need for Bridging Study data. A year and four months have passed since the abortion crime was abolished, but drugs that have been applied for permission by domestic pharmaceutical companies are still being reviewed. According to the press release of the MFDS on the 18th, the MFDS r
- Opinion
- [Desk] R&D capabilities and Moonshot
- by Chon, Seung-Hyun Apr 19, 2022 05:52am
- Pfizer CEO Albert Bourla introduced Pfizer's COVID-19 vaccine development process through a recently published book called "Moonshot." Every step from the decision to develop a COVID-19 vaccine to clinical trials, large-scale production, and transportation was close to impossible, and it created a miracle with prepared R&D capabilities and ju
- Company
- Pharmaceutical industry starts face-to-face marketing
- by Kim, Jin-Gu Apr 18, 2022 05:58am
- As the government decided to completely lift social distancing measures from today (18th), the pharmaceutical bio industry is also actively planning offline marketing events. As large-scale offline events have been virtually impossible for nearly two years, marketers are raising expectations for changes caused by the move. ◆ Abolish so
- Company
- DHP Korea faces reimb. reevaluations for its HA eye drops
- by Nho, Byung Chul Apr 18, 2022 05:58am
- How DHP Korea, a company specializing in eye drops, will be establishing a strategy to defend its sales ahead of the upcoming reimbursement reevaluations for its HA (hyaluronic acid) products next year is drawing attention. In particular, this upcoming risk is highly likely to serve as a testbed to verify the company’s newly appointed CEO Eu
- Policy
- Reimb. suspension on rebate drugs unconstitutional
- by Lee, Tak-Sun Apr 18, 2022 05:58am
- A claim that applying the reimbursement suspension system on illegal rebate drugs that had been abolished in 2018 to acts that had been made before the law was revised can be unconstitutional has been raised. Due to unreasonable aspects of applying the existing law, the claim is that it is more reasonable to retroactively apply the law revi
- Policy
- Utilizing RWD for Re-evaluation of Old Drugs
- by Lee, Hye-Kyung Apr 18, 2022 05:58am
- Discussions were conducted at the Central Pharmacist Review Committee on the criteria for clinical re-evaluation of items licensed on the basis of foreign drug formulas without efficacy evaluation. The drug was Hanall Biopharma's "Blistop (p-Aminomethyl Benzoic Acid)" and was approved on May 16, 2001, and its efficacy expired on April 1.
